Characteristics and Outcome of Adolescents with Acute Lymphoblastic Leukemia (ALL) Differ from Young Children in the B-Cell Lineage but Not in the T-Cell Lineage: Experience of the ALL Israeli National Studies (INS).

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 902-902
Author(s):  
Ronit Elhasid ◽  
Gali Avrahami ◽  
Aya Abramov ◽  
Dina Attias ◽  
Ami Ballin ◽  
...  
Keyword(s):  
T Cell ◽  
Young Children ◽  
Relapse Rate ◽  
Age Groups ◽  
Cell Lineage ◽  
Early Response ◽  
Biological Characteristics ◽  
Age Group ◽  
Younger Patients ◽  
B Lineage

Abstract The outcome of adolescents (≥ 15 years old) with ALL treated on contemporary pediatric ALL protocols has improved and compares favorably with the results of adolescents treated on adult protocols. However, the overall outcome of adolescents is still inferior to that of young children. In order to analyze this difference we compared early response to treatment and biological characteristics of various ALL subtypes (T-cell and non-T-cell), in these age groups. Between January 1989 and June 2008, a total of 942 patients, i.e.,83 (9%) aged ≥ 15 years, 162 (17%) aged 10<15 years and 697 (74%) aged 1<10 years, were enrolled in three ALL Israeli National Studies: INS-89/98 and INS 2003, based on the modified ALL-BFM 90/95, and ALL IC-BFM 2002, respectively. The 7-year event free survival (EFS) and overall survival (OS) in the ALL-INS 89/98 study for the age group of ≥ 15y were 67.1% (± 6.6%) and 66.4% (±6.7%) respectively, compared to 77.3% (±1.9%) and 83.4% (±1.7%) for the age group of 1<10y (p=0.132, p=0.008) respectively. No difference in either EFS or OS was found between the ≥ 15y and 10<15y age groups. In adolescents the incidence of T-ALL was higher compared to that in young children aged 1<10 y (36% vs 18 %;p<0.0001) and similar to the incidence seen in the 10<15y group (30%; p=0.35). In T-ALL no difference in EFS (Fig), relapse rate, or OS, were observed among the age groups. No major differences were seen in patient characteristics, including gender, WBC at diagnosis, BFM-risk factor (RF) and early response to prednisone. In contrast, in the B-lineage ALL, the outcome of adolescents was significantly inferior compared to that in young children (1–10y) in terms of EFS (Fig) and OS [61.4% (± 8.8%) vs 88.1% (±1.7%)(p=0.000)], with a higher relapse rate [25% (± 7.9%) vs 14.5% (±1.8%) (p=0.15)] and higher incidence of death in induction. No significant difference in the outcome was noticed between the ≥ 15y and 10<15y age groups (Fig). Adolescents with B-lineage ALL, when compared to younger patients (1–10y), had increased incidence of males (p=0.016)) and showed a higher WBC count at diagnosis (p=0.061), CNS involvement (p=0.0008), CALLA negative immunophenotype (p=0.002), and trend for poor response to prednisone. Cytogenetic analysis revealed that patients from the ≥ 15y group had a much lower incidence of favorable genetic subgroups: TEL/AML1+ and high hyperdiploidy (>50 chromosomes), higher incidence of Philadelphia chromosome, and normal karyotype compared to younger patients (1<10 y) (p=0.0064). In conclusion: In adolescents the higher incidence of unfavorable biological features in B-lineage ALL could contribute to their inferior results compared to young children. In T-cell ALL, no difference was demonstrated either in the outcome or biological characteristics, among the age groups of patients receiving the ALL-INS treatment (BFM backbone). Figure Figure

scholarly journals PENGELOMPOKAN JUMLAH PENDUDUK BERDASARKAN KATEGORI USIA DENGAN METODE K-MEANS

2019 ◽  
Vol 2 (2) ◽  
pp. 166
Author(s):  
Sahat Sonang ◽  
Arifin Tua Purba ◽  
Ferri Ojak Imanuel Pardede
Keyword(s):  
Young Children ◽  
Human Resources ◽  
Data Processing ◽  
Early Adulthood ◽  
Age Groups ◽  
Early Adolescents ◽  
Age Group ◽  
Late Adolescents ◽  
Economic Level ◽  
The Government

Control of population is one of the tasks of the government in Indonesia. The increase and movement of population in each region makes a certain area to defeat changes in population surging, and this can affect the economic level of the area. This study aims to process the population of Pematangsiantar City in 2018 which is divided into age groups, namely: Toddlers, Young Children, Early Adolescents, Late Adolescents, Early Adolescents, Late Adulthood, Early Adulthood, Elderly, Late Elderly, and Upper Seniors. Data processing is done by using K-Means method clustering in accordance with the population of Pematangsiantar City per district. With this grouping, we can see that the number of population in each sub-district is based on each age group so that we can implement programs that are more appropriate in improving human resources.

New recurring cytogenetic abnormalities and association of blast cell karyotypes with prognosis in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group report of 343 cases

Blood ◽  
2000 ◽  
Vol 96 (7) ◽  
pp. 2543-2549 ◽  
Author(s):  
Nancy R. Schneider ◽  
Andrew J. Carroll ◽  
Jonathan J. Shuster ◽  
D. Jeanette Pullen ◽  
Michael P. Link ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
T Cell ◽  
Pediatric Oncology ◽  
Lymphoblastic Leukemia ◽  
Cell Lineage ◽  
Blast Cell ◽  
Derivative Chromosome ◽  
Oncology Group ◽  
Pediatric Oncology Group ◽  
B Lineage

Abstract To further define the cytogenetic differences between B-cell lineage (B-lineage) acute lymphoblastic leukemia (ALL) and T-cell lineage ALL (T-ALL) and to determine the prognostic value of cytogenetics in childhood T-ALL, the blast cell karyotypes of 343 cases of pediatric T-ALL, the largest series reported to date, were evaluated. Cytogenetics were performed in a single central laboratory, and the children were treated using a single Pediatric Oncology Group protocol. Clear differences between the karyotypic characteristics of B-lineage ALL and T-ALL were confirmed. This study suggests that there may be survival differences associated with some T-ALL blast cell karyotypes. Better survival is associated with only normal karyotypes and with t(10;14) (translocation of chromosomes 10 and 14); worse survival is associated with the presence of any derivative chromosome. Two new recurring chromosome aberrations previously not reported in T-ALL were found: del(1)(p22) and t(8;12)(q13;p13). Ten aberrations found in this series, which were reported only once previously in T-ALL, can now be considered recurring abnormalities in T-ALL. All 12 of these new recurring aberrations are targets for discovery and characterization of new genes that are important in T-cell development and leukemogenesis.

Prognostic Significance Of NPM1 mutations In The Absence Of FLT3-ITD in Older Patients With AML: A SWOG Report

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 1315-1315 ◽  
Author(s):  
Fabiana Ostronoff ◽  
Megan Othus ◽  
Soheil Meshinchi ◽  
John E. Godwin ◽  
Kenneth J. Kopecky ◽  
...  
Keyword(s):  
Risk Factor ◽  
Relapse Rate ◽  
Conflicts Of Interest ◽  
Performance Status ◽  
Prognostic Significance ◽  
Age Groups ◽  
Adverse Outcomes ◽  
Prognostic Impact ◽  
Age Group ◽  
Npm1 Mutation

Abstract Introduction Younger acute myeloid leukemia (AML) patients with a NPM1 mutation but without FLT3-ITD (NPM1+/FLT3-ITD-) have favorable prognosis, but the prognostic significance of these mutations in patients older than 55 years is less clear. Therefore, we evaluated the prognostic impact of the NPM1+/FLT3-ITD- in older AML patients. Methods Samples were obtained from AML patients enrolled onto SWOG trials S9333, S9031, S9500 and S0106 who were ³55 years and received “7+3 like” induction regimens. Cytarabine/daunorubicin (S9031 and S9033) or HiDAC (9500 and S0106) were used for consolidation. Gemtuzumab ozogamicin, either during induction, consolidation, and/or post-consolidation, was administered to some patients enrolled onto S0106. Samples were examined for FLT3, NPM1, DNMT3A, IDH1/2 mutations using previously reported techniques. Results A total of 1,239 patients enrolled in these trials, and pre-treatment samples were available for 156 patients who were older than 55 years (median age of 60 years, range 55-83). NPM1 and FLT3-ITD mutations were present in 33% and 24% of the patients, respectively. The complete remission (CR) rate, 2-year overall survival (OS) and relapse-free survival (RFS) for the entire cohort were 62%, 31% and 32%, respectively. Increased age, unfavorable cytogenetics and FLT3-ITD were associated with a worse OS and RFS. NPM1 mutations were not significantly associated with OS or RFS. Patients were then divided into two age groups, 55-65 and >65 years, based on previous data that favorable prognostic factors such as good-risk cytogenetics have not been shown to be associated with favorable outcomes for AML patients age >65. Both age groups displayed similar patient characteristics (in regards to white blood cell count, bone marrow blast %, cytogenetics, secondary AML, sex and ECOG performance status), with the exception that >65 years group did not include any patients from S0106 or S9500 due to age restrictions for these trials. Patients >65 had a higher relapse rate (P =0.001) and significantly worse OS (P<0.001) and RFS (P=0.007) than those aged 55-65. FLT3-ITD retained its unfavorable prognostic significance for patients age 55-65, while patients >65 years had such a uniformly poor prognosis that this mutation lost much of its prognostic significance. NPM1 mutations were not significantly associated with either OS or RFS in either age group. We then examined the most favorable NPM1+/FLT3-ITD- genotype, which is currently being used to risk-stratify AML patients. NPM1+/FLT3-ITD- was associated with an improved OS in the 55-65 age group (P<0.001), which was similar to previously described results in younger patients (Figure 1A). Additional analyses showed that the favorable impact of this genotype was not due to the inclusion of patients enrolled onto S0106 and S9500 (Figure 1B). In contrast, patients >65 years with the NPM1+/FLT3-ITD- had a low CR rate and high 1-year relapse rate, which translated into a relatively poor 5-year OS (<30%, Figure 1C) that was not significantly different from patients >65 without this genotype (P=0.33). Since mutations in DNMT3A, IDH1/2 have been associated with adverse outcomes for patients with NPM1 mutations, samples with the NPM1+/FLT3-ITD- genotype were examined for these mutations. The frequencies for DNMT3A, IDH1/2 mutations were similar in both age groups, indicating that these mutations were not responsible for the age-dependent findings. Furthermore, multivariate models adjusting for known prognostic covariates showed that the NPM1+/FLT3-ITD- remained independently associated with improved OS for patients age 55-65 but not those >65. Conclusions This study represents one of the largest investigations on the prognostic significance of NPM1+/FLT3-ITD- in older AML patients. The NPM1+/FLT3-ITD- genotype remains a favorable-risk factor for AML patients age 55-65 years but may not be a favorable-risk factor for patients >65 years, at least not for those treated with standard induction followed by conventional consolidation. Disclosures: No relevant conflicts of interest to declare.

Development and Piloting of the Starship Posttraumatic Amnesia Scale for Children Aged Between Four and Six Years

2002 ◽  
Vol 3 (1) ◽  
pp. 34-41 ◽  
Author(s):  
Kris Fernando ◽  
Lynette Eaton ◽  
Morag Faulkner ◽  
Yogi Moodley ◽  
Raylene Setchell
Keyword(s):  
Young Children ◽  
Age Groups ◽  
Operational Definition ◽  
Age Group ◽  
Normal Children ◽  
Posttraumatic Amnesia ◽  
Standard Deviations ◽  
Definition Of

AbstractThe aim of this study was to develop and pilot a posttraumatic amnesia scale (PTA) scale for children aged between four and six years. The scale consists of seven orientation questions and five memory items modelled on the Westmead PTA Scale which assesses posttraumatic amnesia in children from eight years onwards and adults. The sample consisted of 45 four-year-olds, 82 five-year-olds and 49 six-year-old children from a variety of cultural and socioeconomic backgrounds. Children were recruited from hospitals, kindergartens and schools. Results were analysed across age groups using means and standard deviations. The orientation and memory items were analysed separately as well as in combination. Early analyses indicate that the majority of normal children in the four to 6 year age group can answer most of the orientation questions correctly and remember the memory stimuli from day to day. The results indicate that the Starship PTA Scale is suitable for young children aged 4 to 6 years. It is simple and quick to administer and utilises an operational definition of posttraumatic amnesia in terms of measuring continuous memory.

scholarly journals Association Between Tobacco Dependence and Quit Rate

2020 ◽  
Vol 11 (SPL3) ◽  
pp. 1477-1482
Author(s):  
Hemashree J ◽  
Arthi Balasubramaniam ◽  
Manjari Chaudhary
Keyword(s):  
Nicotine Dependence ◽  
Relapse Rate ◽  
Case Reports ◽  
Age Groups ◽  
Tobacco Dependence ◽  
University Hospital ◽  
Age Group ◽  
Chi Square ◽  
Quit Rate ◽  
Tobacco Usage

Tobacco usage is a major cause of death from cancer, cardiovascular disease, pulmonary diseases. Nicotine addiction which causes physical and psychological dependency, might function as a barrier to smoking cessation. This study aimed to find the association between tobacco dependence and quit rate. A retrospective study was conducted using case records of patients visiting University hospital. About 100 case reports containing information on tobacco dependence and quit rate (in terms of a number of relapses) were retrieved and analysed. Descriptive statistics was done to present the sociodemographic details. Chi-square association to find the association tobacco dependence and relapse rate. Tobacco dependence was higher in males compared to females among all the age groups. It was seen that high nicotine dependence was noted among the subjects of the age group 51 - 60 years (3%). Quit rate with less number of relapses was noted among individuals with low tobacco dependence. There was a statistically significant association between tobacco dependence and quit status (p=0.000). Males (36.5%) had more relapse rate compared to females. About 44.4% of patients with medium dependence had a high number of relapses followed by patients with very low dependence (30.56%). Among 18% of patients with high nicotine dependence, 10% of patients had more number of relapses. Very low and low dependence have more number of relapses with no association between nicotine dependence and quit status.

Clinical features and outcome of T-cell acute lymphoblastic leukemia in patients older than 9 years: A single center experience of 110 patients from AIIMS, New Delhi, India.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 7081-7081
Author(s):  
Sunu Lazar Cyriac ◽  
Bivas Biswas ◽  
Sameer Bakhshi ◽  
Atul Sharma ◽  
Ritu Gupta ◽  
...  
Keyword(s):  
T Cell ◽  
Lymphoblastic Leukemia ◽  
Tumor Lysis Syndrome ◽  
Age Groups ◽  
Maintenance Phase ◽  
Total Leucocyte Count ◽  
P Value ◽  
Age Group ◽  
Single Center ◽  
Single Center Experience

7081 Background: It is known that T cell acute lymphoblastic leukemias (ALL) have poorer outcomes than their B cell counterparts. Data on T-ALL in the age group of >9 years from India is minimal. Methods: This is a single institutional analysis of patients of above 9 years who were treated from January 2000 to December 2010. All patients who completed at least 4 weeks of induction therapy were analysed for various outcomes. Results: T-ALL formed 30% of all ALL in this age group. Of the 110 newly registered patients of T-ALL, the median age was 17 years (Range 10-50 years) with an M:F ratio of 5.9:1. Of this 62%, 30% and 18% patients belonged to 10-18, 19-30 and > 31 years age group respectively. Eighteen (19%) and 2 (2%) and 33 (30%) had CSF, testicular and other extramedullary sites involvement respectively. Twenty eight per cent had a total leucocyte count (TLC) of above 100x109/L. Patients available for survival analysis were 104(94.5%). Complete remission (CR)rate was 68.2% and induction mortality was 14.4%. At a median follow up of 56.4 months 5 year leukemia free survival was 52.3% (median not attained). Twenty seven (38%) patients relapsed (median relapse time of 15.2 months, range 0.7 to 47.3 months), 55% during maintenance phase. The 5 year overall survival (OS) was 46.9% (median OS of 35.4 months). The 5 year OS of 10-18, 19-30 and > 31 years age groups were 42.8%, 71% and 16.6% respectively (p value not significant). Not attaining CR in 1st induction, spontaneous tumor lysis syndrome and peripheral blood blast count of > 80% were significant poor prognostic factors for survival. Conclusions: This is one of the largest study of T-ALL outcomes in patients above 9 years from a single center from India. Attainment of CR in 1st induction was the most important risk factor for survival. 5 year OS was 47%.

Decreased Incidence of Type 1 Diabetes in Young Finnish Children

2020 ◽  
Author(s):  
Anna Parviainen ◽  
Anna But ◽  
Heli Siljander ◽  
Mikael Knip ◽  
the Finnish Pediatric Diabetes Register
Keyword(s):  
Type 1 Diabetes ◽  
Young Children ◽  
Age Groups ◽  
Incidence Rates ◽  
Islet Autoimmunity ◽  
Disease Rate ◽  
Age Group ◽  
Group A ◽  
Design And Methods

OBJECTIVE <p>The incidence of type 1 diabetes has been rising for decades, particularly among young children. Between 2006 and 2011 the incidence rate reached a plateau in Finland. In this observational register-based cohort study, we assess recent trends in the disease rate in Finnish children.</p> <p>RESEARCH DESIGN AND METHODS</p> <p>Based on data from the Finnish Pediatric Diabetes Register, we studied the incidence of type 1 diabetes among children under the age of 15 years between 2003 and 2018. We assessed sex-specific incidence rates (IRs) per 100,000 person years (PY) by 4-year time periods in three age groups (0.50–4.99, 5.00–9.99, and 10.00–14.99 years).</p> <p>RESULTS</p> <p>Among the 7,871 children with newly diagnosed type 1 diabetes, the median age at diagnosis increased from 7.88 to 8.33 (<i>P </i>= 0.001), while the overall IR decreased from 57.9/100,000 PY in 2003–2006 to 52.2/100,000 PY in 2015–2018, yielding an IR ratio (IRR) of 0.90 (95% CI 0.85–0.96, <i>P </i>= 0.001). This decline was mainly due to the decrease in the youngest age group [IRR 0.77 (95% CI 0.68–0.87); <i>P </i>< 0.001], being significant both among males and females. In the middle age group, a significant decrease was observed only among females. No changes were observed in the oldest children.</p> <p>CONCLUSIONS</p> <p>The incidence of type 1 diabetes decreased among young Finnish children between 2003 and 2018. Current findings imply that environmental factors driving the immune system towards islet autoimmunity are changing in young children.</p>

Outcomes in Children and Adolescents with a Markedly Elevated White Blood Cell Count (>200,000) at Diagnosis of High Risk Acute Lymphoblastic Leukemia (ALL): A Report from the Children’s Oncology Group.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 1870-1870
Author(s):  
Caroline Hastings ◽  
Harland N. Sather ◽  
Nita L. Seibel ◽  
James Nachman ◽  
Peter G. Steinherz ◽  
...  
Keyword(s):  
T Cell ◽  
Children And Adolescents ◽  
Lymphoblastic Leukemia ◽  
Prognostic Significance ◽  
Early Response ◽  
Entire Study ◽  
Free Survival ◽  
Standard Duration ◽  
B Lineage ◽  
To Receive

Abstract In prior studies, children and adolescents with markedly elevated (ME) WBC≥200,000 had a poor outcome. We examined the outcome of these patients enrolled on CCG l961 (n=250) and compared them to other patients with WBC<200,000 (n=1800). Criteria for CCG-1961 enrollment included age 1–9 years and WBC ≥ 50,000; or age ≥ 10 years with any WBC. Two-thirds of ME WBC patients were male; one third were ≥ 10 years of age, and 7% had CNS disease at diagnosis. Among patients with evaluable immunophenotypes (n=223), 46% had B precursor and 55% had T cell ALL. Event free survival (EFS) at 5 years for ME vs lower WBC patients was 60% and 73%, respectively (p<.0001). Survival (S) at 5 years was 73% vs 82% for ME and lower WBC patients, respectively (p=.0015). EFS for ME B precursor patients was 45% compared to 72% for lower WBC B precursor patients (p<.0001). EFS for ME and lower WBC T cell patients was 71% and 74%. On CCG 1961, rapid early response (RER) patients were randomized to receive stronger or standard intensity therapy and standard or longer intensification. Slow early response (SER) patients received increased intensity therapy and were randomized to receive sequential idarubicin/cyclophosphamide or weekly doxorubicin in intensification. All SER patients received 2 delayed intensifications. EFS for RER ME WBC patients (n=143) was 73% for stronger intensification and 60% for standard intensification. EFS for RER ME WBC was 72% for standard duration and 59% for longer duration intensification. EFS was 61% for SER patients (n=83) with no difference among regimens. Eleven of 103 B lineage ME WBC patients had Ph+ ALL of those there were 8 subsequent events. Patients with CNS 2 had significantly worse outcome (4 year EFS 52%) compared to patients with CNS 3 (4 year EFS 59%) or CNS 1(4 year EFS 68%) status at diagnosis, (p=.04). In conclusion, a ME WBC appears to have no prognostic significance for T cell patients while a ME WBC is highly prognostic for B precursor patients. Stronger intensification improves EFS for RER ME WBC patients as compared to standard intensification. Although the numbers are small, the magnitude of this difference is similar to the outcome of the entire study.

Continuous Decrease of Overall Survival in Patients > 30 Years of Age with Acute Myelogenous Leukemia.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 998-998
Author(s):  
Utz O. Krug ◽  
Wolfgang Berdel ◽  
Susanne Amler ◽  
Maria C. Sauerland ◽  
Bernhard Wörmann ◽  
...  
Keyword(s):  
Overall Survival ◽  
Multivariate Analysis ◽  
Prognostic Factor ◽  
Induction Therapy ◽  
Age Groups ◽  
Myelogenous Leukemia ◽  
Age At Diagnosis ◽  
Age Group ◽  
Free Survival ◽  
Younger Patients

Abstract Abstract 998 Poster Board I-20 Introduction: Age at diagnosis is a well established prognostic factor in acute myeloid leukemia, since elderly patients exhibit a very bad prognosis compared to younger patients. However, little is known about the influence of age within different age groups. Patients and Methods: 2874 patients of > 16 years of age were treated in the AMLCG1999 study of the AML Co-operative Group with a standard- and high-dose cytarabine-containing combination induction therapy (TAD/HAM), standard-dose cytarabine containing consolidation therapy (TAD) and different schedules of postremission therapy (allogeneic or autologous stem cell transplantation, maintenance therapy). Patients were grouped into into 5 age categories (< 30 years, 30 – 44, 45 – 59, 60 – 74 and ≥ 75 years) and were analyzed for remission rate (RR), overall survival (OS), event-free survival (EFS), relapse-free survival (RFS) and freedom from relapse (relapse free interval, RFI). Results: The RR after an intensive induction therapy steadily declined from 76.2% to 44.6% with increasing age (see table). However, despite the superior RR in patients < 30 years these patients displayed a not significantly decreased RFS and RFI in the postremission phase compared to the age group 30 – 44 years. As a result, OS and EFS did not differ between the age groups < 30 years and 30-44 years but decreased with increasing age for the age groups < 45, 45 – 59, 60 – 74 and ≥ 75 years. Younger patients displayed leukocytes > 20,000/μl more often (51.1%, 46.5%, 37.4%, 34.6%, 40.4% for the age groups < 30, 30-44, 45 – 59, 60 – 74 and ≥ 75 years respectively), a higher amount of patients with elevated LDH > 700U/l (39.0%, 31.3%, 24.3%, 20.4%, 20.2%), a higher amount of low risk cytogenetics as defined by the presence of CBF aberrations (20.9%, 14.6%, 8.3%, 3.7%, 4.8%) and the lowest incidence of high risk cytogenetics (19.4%, 20.8%, 23.4%, 29.6%, 21.9%). When adjusted for these risk factors in a multivariate analysis, age remained an independent factor for RR together with the cytogenetic risk profile. Age remained a significant adverse prognostic factor for OS in a multivariate analysis showing a decrease for the age groups < 45 years, 45 – 59 years, 60 – 74 years and ≥ 75 years. RFI was significantly worse in the age group ≥ 60 years versus < 60 years but did not differ within these age groups. Conclusion: Taken together, we found age to be a continuous adverse risk factor for the probability of a complete remission in adult AML patients above 30 years of age at diagnosis receiving an intensive induction treatment. Age has previously been shown to be the strongest independent prognostic factor when patients are stratified between the age groups < 60 and ≥ 60 years of age. In our analysis, we could also demonstrate an influence of the age on overall survival within these age groups. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document